Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 19/20 | 0.70 |
| ▸ | PPARG | P37231 | 12/20 | 0.70 |
| ▸ | PGR | P06401 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.66 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.66 |
| ▸ | PDE4A | P27815 | 1/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.66 |
| ▸ | PPARD | Q03181 | 10/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5991315 | 0.89 | PGR (0.56) | PPARAPPARGPGRADORA3CHRM1 | |
| SCHEMBL5991287 | 0.88 | PPARA (0.67) | PPARAPPARGPPARD | |
| SCHEMBL5991298 | 0.88 | PPARA (0.67) | PPARAPPARGPPARD | |
| SCHEMBL22061785 | 0.88 | PPARA (0.82) | PPARAPPARGPGRADORA3CHRM1 | |
| SCHEMBL6813813 | 0.88 | PPARA (0.76) | PPARAPPARGPPARD | |
| SCHEMBL13524848 | 0.88 | PPARA (0.76) | PPARAPPARGPPARD | |
| SCHEMBL17680417 | 0.86 | PPARA (0.74) | PPARAPPARGPPARD | |
| SCHEMBL12857256 | 0.86 | PPARA (0.74) | PPARAPPARGPPARD | |
| SCHEMBL5391356 | 0.85 | PPARA (0.73) | PPARAPPARGPPARD | |
| SCHEMBL5391355 | 0.85 | PPARA (0.73) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060173204-A1 | New 3-aryl propionic acid derivatives and analogs | ANDERSSON KJELL | 2006-08-03 | — | — | US | claimed |
| US-20040229949-A1 | New 3-aryl propionic acid derivatives and analogs | ANDERSSON KJELL (SE) | 2004-11-18 | — | — | US | claimed |
| US-6630600-B1 | Intermediate for their manufacture, pharmaceutical preparations containing them and the use of the compounds in clinical conditions associated with insulin resistance. | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | claimed |
| EP-1084102-B1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | claimed |
| EP-1084102-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | AstraZeneca AB (SE) | 2001-03-21 | — | — | EP | claimed |
| WO-1999062871-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | claimed |
| US-20060173204-A1 | New 3-aryl propionic acid derivatives and analogs | ANDERSSON KJELL | 2006-08-03 | — | — | US | disclosed |
| US-20040229949-A1 | New 3-aryl propionic acid derivatives and analogs | ANDERSSON KJELL (SE) | 2004-11-18 | — | — | US | disclosed |
| US-6630600-B1 | Intermediate for their manufacture, pharmaceutical preparations containing them and the use of the compounds in clinical conditions associated with insulin resistance. | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | disclosed |
| EP-1084102-B1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| EP-1084102-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | AstraZeneca AB (SE) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999062871-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229949-A1 | New 3-aryl propionic acid derivatives and analogs | GPR119, INSR, IRS1 | PPARA 11/4885PPARG 22/4885PGR 1370/4885 |
| US-20060173204-A1 | New 3-aryl propionic acid derivatives and analogs | GPR119, INSR, IRS1 | PPARA 11/4885PPARG 22/4885PGR 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.